NHP-Based Pharmacology and Pharmacodynamic Services: Driving Translational Drug Development
Prisys Biotechnologies (Shanghai) runs non-human primate (NHP)-based pharmacology and pharmacodynamic (PD) studies for pharmaceutical and biotech companies. The work sits on one AAALAC-accredited site in Shanghai, so dosing, imaging, sampling and bioanalysis come from a single protocol.
Core Strengths of Prisys Biotech
1. Broad Spectrum of Validated NHP Disease Models
|
Therapeutic Area
|
Representative NHP Models
|
Key Endpoints & Assessments
|
|
CNS & Neurology
|
3D behavior analysis, fMRI/MRI, neurofunctional evaluation
|
|
|
Immunology & Inflammation
|
Joint imaging, flow cytometry, cytokine biomarkers (IL-6, TNF-α, CRP)
|
|
|
Hematology & Coagulation
|
aPTT, bleeding/thrombosis assessment, Hb measurement
|
|
|
Renal Diseases
|
CKD (UUO), AKI
|
Renal function (CREA, UREA), histopathology, ultrasound/MRA
|
|
Metabolic Disorders
|
MRI liver fat quantification, OGTT, insulin resistance, lipid panel
|
|
|
Glaucoma, Retinitis Pigmentosa, Retinal Neovascularization
|
OCT, FFA, fERG
|
2. Translational Technology Platforms
|
Platform
|
Key Features
|
Applications
|
|
Sub-millimeter precision, real-time visualization
|
Targeted CNS injection, coverage mapping
|
|
|
Supports aerosol/dry powder; imaging validation (CT/MRI)
|
Non-invasive CNS drug delivery
|
|
|
Minimally invasive vascular drug infusion
|
Targeted perfusion (liver, kidney, heart) + PK sampling
|
|
|
Markerless 3D motion capture, deep learning analysis
|
Objective behavior quantification in CNS, pain, RA, safety
|
|
|
MRI, CT, DSA, Ultrasound operated by ex-clinical radiologists
|
Functional/structural disease imaging, biomarker quantification
|
|
|
Bioanalysis & Sampling
|
Flow cytometry, ELISA/MSD, CSF, BALF, tissue biopsies
|
Biomarker profiling, immune response analysis
|
3. Facilities And Team
|
Capability
|
Details
|
|
Facility Scale
|
4,000 m² AAALAC-accredited center in Shanghai
|
|
Animal Capacity
|
Up to 500 cynomolgus monkeys
|
|
Infrastructure
|
Sterile operating rooms, laminar flow ICU, SPF housing
|
|
Team Expertise
|
Preclinical physicians, imaging specialists, pharmacologists
|
Comprehensive Service Portfolio
Prisys provides NHP pharmacology and PD support through the full study, including:
- Efficacy and mechanism-of-action studies
- Biomarker discovery and validation
- Imaging, behavior, and clinical pathology assessments
- IND-enabling study design and data packages
Partner with Prisys Biotech
Prisys runs these studies in cynomolgus monkeys on a platform that already includes the models, the imaging, the surgical capacity and the bioanalysis. A sponsor brings the candidate and the clinical question; the design and the data package are built around them. Contact us today to discuss how NHP-based pharmacology and pharmacodynamic services fit a specific program.
FAQ
Q: Why are NHP models important in pharmacology and PD research?
A: Pharmacology and PD work asks whether a drug produces the intended biological effect at a tolerable exposure. NHP models answer that in a species whose target sequence, receptor expression and immune-cell composition sit close to human.
Q: How does Prisys ensure data relevance to human clinical trials?
A: Imaging is acquired on clinical sequences and read by former clinical radiologists, so a lesion is described the way a hospital would. Sampling covers CSF, BALF and tissue biopsies, so the same markers can be followed from dosing onward.
Q: What measures are taken for animal welfare and regulatory compliance?
A: Prisys is fully AAALAC-accredited and operates under GLP-like standards. Our facilities include sterile operating rooms, laminar flow ICUs, and pathogen-free housing. Animal welfare and ethical compliance are at the core of all our studies.
Q: Can Prisys customize pharmacology and PD studies for specific drug programs?
A: Yes. We design studies around the therapeutic indication, delivery route, and regulatory needs of our partners, and we provide data packages to support IND filing and clinical trial planning.
